<DOC>
	<DOC>NCT02181816</DOC>
	<brief_summary>The purpose of this survey is to evaluate the safety and efficacy of long-term use of azilsartan/amlodipine combination tablets LD &amp; HD (Zacras Combination Tablets LD &amp; HD) in hypertensive patients in daily medical practice.</brief_summary>
	<brief_title>Azilsartan/Amlodipine Combination Tablets LD &amp; HD Specified Drug-use Survey "Long-term Use Survey"</brief_title>
	<detailed_description>This survey was designed to evaluate the safety and efficacy of long-term use of azilsartan/amlodipine combination tablets LD &amp; HD (Zacras Combination Tablets LD &amp; HD) in hypertensive patients in daily medical practice. For adults, one azilsartan/amlodipine combination tablet (20 mg/2.5 mg [for LD tablets] or 20 mg/5 mg [for HD tablets] of azilsartan/amlodipine) is administered orally once daily. Azilsartan/amlodipine combination tablets should not be used as the first-line drug for the treatment of hypertension.</detailed_description>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Hypertensive patients Hypertensive patients who meet any of the following conditions, [1] to [3], are excluded from the survey: 1. Patients with a history of hypersensitivity to any of the ingredients of Zacras Combination Tablets or other dihydropyridine drugs 2. Patients who are pregnant or having possibilities of being pregnant 3. Diabetic patients taking aliskiren fumarate (excluding those with markedly poor blood pressure control even after other antihypertensive treatment)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>